Materials and Methods
Cell Lines and Cultures. Human brain astrocytoma (MOGGCCM), human rhabdomyosarcoma͞medulloblastoma (TE671), human neuroblastoma (SKNAS), and human thyroid carcinoma (FTC238) were obtained from the European Collection of Cell Cultures (Center for Applied Microbiology and Research, Salisbury, U.K.). Human Caucasian colon adenocarcinoma (LS180) and human breast carcinoma (T47D) were gifts from Lublin Medical University, Lublin, Poland. Human Caucasian lung carcinoma (A549) and human colon adenocarcinoma (HT29) were obtained from the Institute of Immunology and Experimental Therapy (Polish Academy of Sciences, Wroclaw, Poland). SKNAS, TE671, T47D, and LS180 were grown in 1:1 mixture of DMEM (D6421, Ca 2ϩ concentration of 1.05 mM) (Sigma) and nutrient mixture F-12 Ham (Ham's F-12) (Sigma) supplemented with 10% FBS (Life Technologies, Paisley, Scotland). FTC238 was grown in the same culture medium supplemented with 5% FBS. HT29 was grown in DMEM (D6046, Sigma; Ca 2ϩ concentration of 1.8 mM) supplemented with 10% FBS. MOGGCCM and A549 were grown in 2:1 mixture of DMEM (D6046)͞Ham's F-12 (Sigma) supplemented with 10% FBS. Human skin fibroblasts was a laboratory strain obtained by outgrowth technique from a skin explant, embedded in 2% agar and cultured in 1:1 mixture of DMEM and nutrient mixture Ham's F-12. Bone marrow stromal cell culture was established from bone marrow obtained from a healthy donor, mixed 1:1 with Iscove's Modified Dulbecco's Medium (IMDM, Life Technologies) containing 0.2% methyl cellulose (Sigma), and left for 45 min in room temperature. After completion of erythrocyte sedimentation, nuclear cells were collected, washed twice in IMDM containing 2% FBS (Life Technologies), and centrifuged at 1,500 rpm for 5 min. Cells were suspended in growth medium consisting of IMDM supplemented with 10% FBS, 10% horse serum (Life Technologies), 10 g͞ml hydrocortisone (Sigma), and antibiotic-antimycotic solution (Life Technologies, 1 ml͞ 100 ml of culture medium). Human skin fibroblasts and bone marrow stromal cells were used as nonmalignant proliferating cell lines. Cultures were kept at 37°C in a 95% air͞5% CO 2 atmosphere. As Ca 2ϩ -free medium, a minimum essential medium M8167 (Sigma) was used. (ϩ)Dizocilpine and GYKI52466 were obtained from Research Biochemicals. (Ϫ)Dizocilpine, ketamine, memantine, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline (NBQX), and 1-(4Ј-aminophenyl)-3,5-dihydro-7,8-dimethoxy-4H-2,3-benzodiazepin-4-one (CFM-2) were obtained from Tocris (Bristol, U.K.). Cyclophosphamide was obtained from ICN Biomedicals (Eschwege, Germany). Cisplatin and vinblastin were obtained from Sigma and thiotepa from Lederle Laboratories (Pearl River, NY). To determine the time course of antiproliferative action of glutamate antagonists, tumor cell lines such as MOGGCCM, T47D, A549, TE671, or FTC238 were exposed for 24, 48, 72, 96, and 120 h to different concentrations of (ϩ)dizocilpine or GYKI52466. For threeAbbreviations: NMDA, N-methyl-D-aspartate; AMPA, ␣-amino-3-hydroxy-5-methyl-4-isoxazole-propionate; MTT, 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide; LDH, lactate dehydrogenase; GYKI52466, 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine; NBQX, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline; CFM-2, 1-(4Ј-aminophenyl)-3,5-dihydro-7,8-dimethoxy-4H-2,3-benzodiazepin-4-one.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. dimensional cultures, spongostan biodegradable gelatin sponge (Spongostan; Ferrosan, Copenhagen) was used. Tumor cells were immobilized on spongostan discs (0.06 cm 3 ) at a density of 1 ϫ 10 5 in 5-ml tubes. Tubes were subjected to constant rotary shaking at 150 rpm at 37°C. Culture medium was renewed every 48 h, and tumor growth was assessed by cell counting after trypsinization of the gelatin mix.
Cell Viability Assay. The yellow tetrazolium salt 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is metabolized by viable, metabolically active cells to purple formazan crystals. Tumor cells grown in 96-well multiplates were incubated for 4 h with MTT solution (Cell proliferation kit I; Roche Molecular Biochemicals). Formazan crystals were solubilized overnight, and the product was quantified spectrophotometrically by measuring absorbance at 570 nm wave length by using a Victor Multilabel Counter (Perkin-Elmer-Wallac, Freiburg, Germany).
Cell Proliferation Assay. Tumor cells were incubated with BrdUrd (BrdUrd labeling and detection kit III; Roche Molecular Biochemicals) for 18 h. Cells were subsequently fixed with 0.5 M ethanol͞HCl and then were incubated with nucleases to partially digest DNA. Monoclonal anti-BrdUrd antibodies conjugated to peroxidase were subsequently added and detected by using 2,2Ј-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) substrate. Quantitation was performed colorimetrically at 405-490 nm wavelength.
Cytotoxicity Assay. A cytotoxicity detection kit based on measurement of lactate dehydrogenase (LDH) activity was used (Roche Molecular Biochemicals). The culture supernatant was collected and incubated with substrate mixture. LDH activity was determined by a coupled enzymatic reaction whereby the tetrazolium salt p-iodonitrotetrazolium violet is reduced to formazan. The amount of formazan formed is directly related to LDH activity in the supernatant. Absorption was measured at 490 nm. For visualization of degenerating cells, cultures were treated with 0.4% trypan blue (Sigma).
Immunocytochemistry and Light Microscopy. Cells fixed in 4% paraformaldehyde were incubated for 24 h with primary antibody against the NR1 (AB 1516, 1:200; Chemicon) or GluR2͞3 (AB 1506, 1:100; Chemicon) glutamate receptor subunits. Antibody detection was performed by using a multilink streptavidin-biotin complex method, and visualization was achieved by using diaminobenzidine chromagen method (PK-6100, Vector; Boehringer Ingelheim). Negative control samples were incubated in primary antibody diluent only. For light microscopy, cells plated on plastic round coverslips at a density of 1 ϫ 10 4 were allowed to grow for a 72-to 96-h period and were subsequently fixed in 4% paraformaldehyde in phosphate buffer, dehydrated, and stained with methylene blue͞azure II.
Scanning Electron Microscopy. Cells were seeded at a density of 0.5-1 ϫ 10 4 on 13-mm round plastic coverslips (Thermanox, Nunc) or at a density of 3-6 ϫ 10 5 on 24-mm round polycarbonate membrane filters (0.4-m pore size) in 6-well transwells (Costar) and grown for 96 h in the presence or absence of dizocilpine (100 M) or GYKI52466 (100 M). Cells were fixed with 2% glutaraldehyde in PBS, pH 7.4, and processed for scanning electron microscopy. 
Results
Glutamate Antagonists Decrease Tumor Cell Proliferation. Proliferation of tumor cells was decreased in cultures exposed to the NMDA antagonist (ϩ)dizocilpine (Fig. 1A) or the AMPA antagonist GYKI52466 (Fig. 1B) in a concentration-dependent manner as measured by means of the MTT assay, whereas proliferation of human skin fibroblasts and bone marrow stromal cells was unaffected by exposure to both antagonists ( Fig. 1 A  and B) . Time-course studies revealed that antiproliferative effect was already established after 24 h and did not differ in intensity between 24-and 120-h exposure of MOGGCCM, T47D, A549, TE671, or FTC238 tumor cells to dizocilpine or GYKI52466. The antiproliferative effect of dizocilpine was reproduced in a threedimensional neuroblastoma cell culture grown on spongostan (Fig. 1C) .
The effect of glutamate antagonists on tumor cell proliferation was attributed both to decreased cell division, as determined by measurements of incorporation of BrdUrd, and increased cell death, as determined by measurements of LDH activity ( Fig. 2A) and trypan blue exclusion (Fig. 2B ). Colon adenocarcinoma (HT29), astrocytoma (MOGGCCM), breast carcinoma (T47D), and lung carcinoma (A549) were most sensitive to the cytostatic effect of the NMDA antagonist dizocilpine (Fig. 1 A) , whereas breast carcinoma (T47D), lung carcinoma (A549), colon adenocarcinoma (HT29), and neuroblastoma (SKNAS) were most sensitive to the AMPA antagonist GYKI52466 (Fig. 1B) . The threshold concentrations of dizocilpine or GYKI52466 required to elicit antiproliferative effects ranged between 1 and 50 M ( Fig. 1 A and B) . Significant antiproliferative effect of dizocilpine was detected at concentrations as low as 1 M in colon adenocarcinoma cells (HT29) and as low as 10 M in astrocytoma (MOGGCCM) cells. In lung carcinoma (A549), neuroblastoma (SKNAS), breast carcinoma (T47D), Caucasian colon adenocarcinoma (LS180), rhabdomyosarcoma͞medulloblastoma (TE671), and thyroid carcinoma (FTC238) cells, antiproliferative effects of dizocilpine were seen at 50 M (Fig. 1 A) . Similarly, GYKI52466 significantly inhibited proliferation of colon adenocarcinoma cells (HT29) at concentrations as low as 1 M and of breast carcinoma (T47D) and Caucasian colon adenocarcinoma (LS180) cells at concentrations as low as 10 M (Fig. 1B) . In the remaining tumor cell lines, antiproliferative effects of GYKI52466 were detected at 50 M (Fig. 1B) . Such concentrations of glutamate antagonists are required to modulate NMDA-or AMPA-mediated currents in nonneuronal tissues such as osteoblasts and osteoclasts (17, 18) or to inhibit migration of embryonic cortical neurons (12) . The antiproliferative effect of dizocilpine or GYKI52466 was absent in lung carcinoma (A549) and rhabdomyosarcoma͞medulloblastoma (TE671) cells grown in the Ca 2ϩ -free medium (Fig. 3 A-D) , indicating that blockade of Ca 2ϩ influx was involved in mediating the antiproliferative effect of glutamate antagonists.
To confirm that the antiproliferative effects of dizocilpine or GYKI52466 were mediated via NMDA or AMPA receptor͞ion channel complexes, several NMDA and AMPA antagonists were tested in lung carcinoma (A549) and rhabdomyosarcoma͞ medulloblastoma (TE671) cells. The NMDA antagonists ketamine and memantine reproduced the antiproliferative effect of dizocilpine ( Fig. 3 A and C) . The AMPA antagonists NBQX and CFM-2 reproduced antiproliferative effects of GYKI52466 in lung carcinoma and rhabdomyosarcoma͞medulloblastoma cells (Fig. 3 B and D) . (Ϫ)Dizocilpine, the less active enantiomer of dizocilpine, was significantly less effective than (ϩ)dizocilpine in lung carcinoma [F A549 (1,80) ϭ 128.52, P Ͻ 0.001] or rhabdomyosarcoma͞medulloblastoma [F TE671 (1,80) ϭ 268.60, P Ͻ 0.001] cells, indicating stereoselectivity for the NMDA channel blockade (Fig. 3 A and C) .
Tumor Cell Proliferation and Glutamate. To test whether glutamate may stimulate proliferation of tumor cells, lung carcinoma (A549) and rhabdomyosarcoma͞medulloblastoma (TE671) cells were exposed to different concentrations of glutamate (1-10 mM) and proliferation was evaluated after 96 h by means of the MTT assay. Glutamate did not affect proliferation of lung carcinoma or rhabdomyosarcoma͞medulloblastoma cells in a medium containing 10% serum. However, glutamate stimulated the proliferation of lung carcinoma cells in the serum-deprived medium or medium supplemented with serum-replacement me- dium. In the serum-replacement medium, glutamate stimulated the proliferation of lung carcinoma cells in a concentrationdependent manner (0.5-10 mM) with a maximum of 21 Ϯ 3% at 10 mM (n ϭ 4). These observations indicate that glutamate may have a trophic effect on lung carcinoma cells. Similarly, NMDA (10-250 M), serine (100-500 M), or ␣-amino-3-hydroxy-5-tert-butyl-4-isoxazole-propionate (ATPA; 0.1-10 M) did not affect proliferation of lung carcinoma or rhabdomyosarcoma͞ medulloblastoma cells in medium containing 10% serum. NMDA and serine, but not ATPA, stimulated the proliferation of lung carcinoma cells in serum-deprived or serum-replacement medium.
Immunocytochemistry. To verify that tumor cells express subunits forming NMDA or AMPA receptor͞ion channel complexes, we applied immunocytochemistry to colon adenocarcinoma (LS180), astrocytoma (MOGGCCM), lung (A549) and breast (T47D) carcinoma, neuroblastoma (SKNAS), rhabdomyosarcoma͞medulloblastoma (TE671), and thyroid carcinoma (FTC238) cells as well as to human skin fibroblasts by using antibodies against either the NR1 subunit of the NMDA receptor͞ion channels or the GluR2͞3 subunits of the AMPA receptor͞ion channels. A positive immunostaining for both subunits was detected in all tumor cell lines, whereas no immunoreactivity was present in human skin fibroblasts and tumor cells not exposed to primary antibodies.
Glutamate Antagonists Alter Morphology and Limit Migration of
Tumor Cells. To evaluate the effect of glutamate antagonists on tumor cell morphology and migration, lung carcinoma (A549), rhabdomyosarcoma͞medulloblastoma (TE671), and thyroid carcinoma (FTC238) cells were exposed to the NMDA antagonist dizocilpine (100 M) or the AMPA antagonist GYKI52466 (100 M) for 96 h, and their morphology was examined by light and scanning electron microscopy. Light microscopy revealed that dizocilpine induced rounded cell appearance with prominent vacuoles in the cytoplasm, whereas exposure to GYKI52466 produced less prominent vacuoles and shrinkage of the cells. Electron microscopy revealed that tumor cells displayed an invasive phenotype with marked membrane ruffling and numerous pseudopodia (Fig. 4 A and D) . In contrast, tumor cells exposed to glutamate antagonists displayed a noninvasive phenotype with fewer pseudopodial protrusions (Fig. 4 B and C) .
To test the hypothesis that glutamate antagonists may decrease tumor cell locomotion and invasiveness, we examined motility of lung carcinoma (A549), rhabdomyosarcoma͞ medulloblastoma (TE671), and thyroid carcinoma (FTC238) cells exposed to NMDA or AMPA antagonists. For that purpose, cells were plated on polycarbonate membrane filters with 3-m pore size in the presence and absence of dizocilpine or GYKI52466. In cultures exposed to dizocilpine or GYKI52466, fewer cells migrated through the filters than in control cultures (Fig. 4E) .
Glutamate Antagonists Enhance Tumoricidal Effects of Cytostatic
Drugs. Lung carcinoma (A549), astrocytoma (MOGGCCM), neuroblastoma (SKNAS), and rhabdomyosarcoma͞medullo-blastoma (TE671) cells were subjected to treatment with cyclophosphamide, cisplatin, thiotepa, or vinblastin and either dizocilpine (100 M) or GYKI52466 (100 M). The cytostatic drugs decreased tumor cell viability in a concentration-dependent manner. This effect was enhanced in all cell lines tested by both (ϩ)dizocilpine and GYKI52466. Fig. 5 shows enhancement of antiproliferative effect of cyclophosphamide and thiotepa by (ϩ)dizocilpine and GYKI52466 in rhabdomyosarcoma͞ medulloblastoma and neuroblastoma cells. Comparable effects were observed in lung carcinoma and astrocytoma cells subjected to (ϩ)dizocilpine or GYKI52466 and cyclophosphamide or thiotepa. Enhancement of antiproliferative effects of cytostatic agents by glutamate antagonists was due to enhanced tumor cell death as demonstrated by means of the LDH assay and to decreased cell division as demonstrated by means of the BrdUrd incorporation assay. With the use of trypan blue staining, both (ϩ)dizocilpine and GYKI52466 were found to enhance toxicity of cytostatic drugs at concentrations as low as 10 M.
Discussion
Glutamate antagonists inhibited division and migration, enhanced death and altered morphology of tumor cells in vitro resembling cytostatic drugs used in therapy of cancer. Antiproliferative effect of the NMDA antagonist dizocilpine could be reproduced by two other NMDA antagonists memantine and ketamine suggesting receptor͞ion channel specificity. It was also stereoselective confirming involvement of NMDA receptor͞ion channel complexes. Antiproliferative effect of GYKI52466 could be reproduced by two other AMPA antagonists CFM-2 and NBQX implicating involvement of AMPA receptor͞ion channel complexes. Furthermore, tumor cells displayed immunoreactivity for subunits NR1 and GluR2͞3 indicating that they express membrane proteins similar to those that form NMDA or AMPA receptor͞ion channel complexes (19) . Glutamate stimulated the proliferation of tumor cells in serum-deprived culture media. The stimulatory effect of glutamate on tumor growth under serum deprivation suggests that glutamate itself can elicit trophic effect on tumor cells.
Ca 2ϩ was identified as a key mediator of antiproliferative action of glutamate antagonists because tumor cells grown under Ca 2ϩ deprivation were resistant to the antiproliferative effects of is necessary for cell division, homeostasis, and survival (22) (23) (24) and regulates protein trafficking through the nuclear membrane (25) . Ca 2ϩ is also essential for formation of cell processes; it regulates axon extension and pathfinding, controls formation of pseudopodia, and affects migration (26) (27) (28) (29) . Glutamate receptor͞ion channel complexes, including the embryonic ones, are permeable to Ca 2ϩ (30) (31) (32) . Little is known about functional properties of receptor͞ion channel complexes on tumor cells responding to glutamate. Glutamate can depolarize membranes and may lead to elevation of intracellular Ca 2ϩ in astrocytoma or neuroblastoma cells (33, 34) . The resting membrane potential ranges in tumor cells between Ϫ30 and Ϫ50 mV (35, 36) . Patch clamp recordings in neurons demonstrate that at such membrane potentials Mg 2ϩ block of NMDA channels is reduced and that AMPA channels become permeable to cations (37, 38) . Should this apply to tumor cells, then the glutamate-regulated ion channels in tumor cell membranes should become more permeable to ions regardless of whether or not the glutamate-binding site is occupied by agonists. This assumption implies that glutamate-dependent receptor͞ion channel complexes on tumor cells could contribute to regulation of proliferation and migration of tumor cells via modulation of Ca 2ϩ homeostasis, as they do with neuronal progenitors during embryogenesis (39) .
Tumor cell lines demonstrated different preferential susceptibility to antiproliferative action of glutamate antagonists in vitro. Tumors of peripheral origin responded favorably to either NMDA or AMPA antagonists, whereas those derived from neuronal and glial tissues were less sensitive to glutamate antagonists. Such susceptibility differences could aid the design of optimal chemotherapeutic regimens taking into account the tissue of tumor origin.
NMDA and AMPA antagonists enhanced tumoricidal effects of cytostatic drugs in vitro by inhibiting tumor cell proliferation and enhancing tumor cell death. These observations suggest that glutamate antagonists possess anticancer potential, which could add to existing therapies of cancer. Because glutamate NMDA and AMPA receptor͞ion channel complexes on tumor cells may differ from those of mature receptor͞ion channel complexes, the design of novel drugs with fewer side effects seems feasible. In addition, NMDA and AMPA antagonists, which do not penetrate the blood-brain barrier and therefore do not cause neurological side effects, may be suitable for therapy of peripheral cancers.
